Benjamin Soffer – CEO
Benjamin Soffer joined the Technion as head of T3 – Technion Technology Transfer office in 2005. As part of his duties at T3, Mr. Soffer is responsible for the establishment of startup companies and the commercialization of technologies arising from the Technion research. His Experience spans over 25 years in the areas of investment, industry and government in Israel, Europe, and the United States. In addition, Mr. Soffer serves as CEO of AMIT, a Technion Incubator for biomedical innovation; CEO of the Technion DRIVE Accelerator, and Chairman of the ITTN – The Israeli Technology Transfer Organization. In addition Mr. Soffer serves on the boards of directors of numerous high growth companies. Prior to his position at the Technion, Mr. Soffer served as managing director of TopNotch Capital – and was as an investment advisor at Highbridge Capital. Between 1999 and 2003 he served as Israel’s Economic attaché in Boston. There, Mr. Soffer was responsible for enhancing economic and business relations between Israel and the US Northeast region through private equity investments, joint ventures and trade. Prior to his tenure in Boston, Mr. Soffer served as special advisor to Dr. Orna Berry, Israel’s chief scientist at the Ministry of Industry and Trade (currently known as Israel Innovation Authority) , where played a pivotal role in the initiation and implementation of innovative R&D programs. A certified lawyer in Israel and in the state of New York, Mr. Soffer has interned at Israel’s Supreme Court and studied law at Tel Aviv University and at Ludwig Maximilian University in Munich. Additionally, he studied economics and business administration at Bar – Ilan University.
Yaron Daniely – PhD. MBA
Dr. Yaron Daniely has been the President and Chief Executive Officer of Yissum Ltd. Since June 2017. Between 2010 and 2017, he was the President, CEO and a Director of Alcobra Ltd (NASDAQ:ARCT). Immediately prior to joining Alcobra and since 2007, Dr. Daniely was the President and Chief Executive Officer of NanoCyte, Inc., a company that develops transdermal delivery technologies based in Caesarea, Israel. Before NanoCyte and from 2004, Dr. Daniely was the General Manager of Gamida Cell—Teva Joint Venture Ltd., a joint venture company that acquired an exclusive license to develop and commercialize a Phase 3-stage cell therapy product for treatment of Leukemia and Lymphoma based in Jerusalem, Israel. From 2003-2007, Dr. Daniely also served as the Vice President of Business Development of Gamida Cell Ltd., and engaged in several licensing and financial transactions for the Company. In addition, he co-founded and served as a director of Bioblast Ltd. (NASADQ:ORPN). Dr. Daniely holds a Ph.D. from the Sackler Institute of Graduate Biomedical Sciences at the New York University School of Medicine. Following his doctoral program, Dr. Daniely served as an NIH Visiting Fellow in its Cell Biology section and a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. Subsequently, he received an Executive M.B.A. from the Technion, Israel Institute of Technology. Dr. Daniely co-founded Israel’s first M.B.A. program specializing in Biomedical Management at the College of Management Academic Studies (Rishon Letzion, Israel) and has served as the program’s Managing Director since its inception.
Gil Granot-Mayer, Yeda Research and Development Co. Ltd.
Orna Harel, Gavish, Technology Transfer of Migal, Galilee Research Institute
Sylvie Luria, Tel Hashomer Ltd, the Chaim Sheba Medical Center.
Venue & Opening Hours
David Intercontinental Hotel, Tel-Aviv.
Monday, Oct. 22nd 2018, 09:00 – 17:00